Predicting ILD from Hypersensitivity Pneumonitis
Trial Objectives
Researchers believe they will be able to predict which patients with chronic Hypersensitivity Pneumonitis (HP) will develop interstitial lung disease (ILD) by looking at their genes and biomarkers in their blood. For this observational study, researchers will collect samples and data from participants with rapidly progressing HP and slowly progressing HP to look for patterns that can help predict the development of ILD and form specialized treatment plans.
Who Can Participate
Adults who have been diagnosed with Hypersensitivity Pneumonitis (HP).
Age: 18-90 Gender: Any
Estimated Time Commitment
Clinic visits every 6 months over approximately 2 years (4 visits total)
Payment & Reimbursement
Payment: Not Provided
Travel Reimbursement: Not Available
Trial Contact
For more information, contact:
Elizabeth Del Real
303.398.1172
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Investigator Initiated with funding from Boehringer Ingelheim
Principal Investigators
Evans Fernández, MD, MS
Co-Investigators
-
Tristan J. Huie, MD
-
Rebecca C. Keith, MD
-
Lisa A. Maier, MD, MSPH, FCCP, ATSF
-
Michael P. Mohning, MD
-
Joshua J. Solomon, MD
-
Zulma X. Yunt, MD